The GNRH1 Knockout PaTu 8988t Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the GNRH1 gene has been disrupted. This product provides a heterogeneous pool of knockout cells derived from the PaTu 8988t pancreatic cancer line, enabling loss-of-function studies of gonadotropin-releasing hormone (GnRH) signaling. The polyclonal format preserves the genetic diversity of edited cells, avoiding clonal artifacts, and is suitable for functional assays requiring a representative knockout model.
The parental PaTu 8988t cell line is a well-characterized epithelial cell line established from a liver metastasis of a human pancreatic ductal adenocarcinoma. This line harbors oncogenic mutations in KRAS and TP53, mirroring the genetic landscape of aggressive pancreatic tumors. PaTu 8988t cells are widely employed to study pancreatic cancer cell biology, including proliferation, invasion, and metastasis, and serve as an ideal host for investigating the interplay between GNRH1 signaling and established oncogenic drivers.
GNRH1 encodes the neuropeptide gonadotropin-releasing hormone, a master regulator of the reproductive axis. Upon binding to its cognate receptor, GNRHR, GnRH activates multiple G protein-dependent signal transduction cascades. The ligand?Creceptor interaction couples to G??q/11 (encoded by GNAQ/GNA11) and G??s (GNAS), triggering phospholipase C?? (PLCB)-mediated production of inositol trisphosphate and diacylglycerol, leading to calcium mobilization and protein kinase C (PKC) activation, which subsequently activates the RAF?CMEK?CERK1/2 (MAPK1/3) pathway. Concurrently, G??s stimulates adenylyl cyclase, increasing cAMP levels and activating PKA, which phosphorylates the transcription factor CREB. These pathways converge on the regulation of downstream targets such as the LH and FSH ??-subunit genes, as well as AKT and other effectors. Upstream, GNRH1 expression is regulated by kisspeptin (KISS1), sex steroids, and neuropeptides like neurokinin B, while receptor signaling is modulated by interacting proteins including ??-arrestin 1/2 and calmodulin.
In pancreatic ductal adenocarcinoma cells, locally produced GnRH is thought to exert autocrine/paracrine effects that promote proliferation, migration, and invasive behavior. By disrupting GNRH1 expression in PaTu 8988t cells, this knockout model permits direct assessment of the tumorigenic contribution of endogenous GnRH signaling. PaTu 8988t??s KRAS and TP53 mutation status further enables investigation of potential cross-talk between GnRH-activated pathways and key oncogenic signaling nodes. Loss of GNRH1 is expected to attenuate downstream GNRHR-mediated activation of ERK1/2 and AKT, providing a clean system for mechanistic dissection.
Typical applications include functional analysis of autocrine GnRH signaling in pancreatic cancer, validation of GNRHR as a therapeutic target, and studies on the mechanisms of GnRH analog action. The knockout cells can be employed in a variety of assays: Western blotting for GNRH1, GNRHR, and phospho-ERK; RT-qPCR for downstream targets; MTT and BrdU proliferation assays; transwell migration and invasion tests; phospho-signaling flow cytometry; and apoptosis measurement with Annexin V. They are also suitable for RNA-seq transcriptome profiling to comprehensively characterize pathway alterations. For technical details and ordering information, please contact Ascent Research.
